Gilead SUPHO01-ENHANCEIII AML
Open
Main info
- Identificatie:
- SUPHO01-ENHANCEIII
- Sponsor:
- Gilead
- Working group party:
- Leukemia
- Stadium:
- 1st lijn
- Echelon:
- Level C-HIC&C-SCT
- Included patients:
-
44(of 43)
- Active sites:
-
18(of 19)4 sites are pending
- Title:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Evaluating the Safety and Efficacy of Magrolimab versus Placebo in
Combination with Venetoclax and Azacitidine in Newly Diagnosed,
Previously Untreated Patients with Acute Myeloid Leukemia Who Are
Ineligible for Intensive Chemotherapy
Timeline
Scheduled
Actual
2023
20 jan.
On Hold
2023
01 feb.
Activated
News
01FEB2023: Europe screening and enrollment is re-open again.
December 2022:
HOVON is giving support to GILEAD for the conduct of the SUPHO01-ENHANCE III study.
The trial management will be performed by ICON.
However, if you have questions f.i. for the coordinating HOVON investigator G. Huls (UMCG) please contact us.
Details
- Phase:
- Prospective double-blind randomized phase III study
- Monitoring Type:
- Study Specific
- Objectives:
Participating Sites
Site
22 results
Order by
Accrual rate
Activation date
BE-Liege-CHULIEGE
8
17 nov. 2022
NL-Groningen-UMCG
7
13 dec. 2022
BE-Haine-Saint-Paul-JOLIMONT
5
26 sep. 2022
NO-Oslo-OSLOUH
4
07 nov. 2022
NL-Den Bosch-JBZ
3
23 nov. 2022
CH-Bern-INSEL
2
30 mrt. 2023
NL-Amersfoort-MEANDERMC
2
28 nov. 2022
NL-Leeuwarden-MCL
2
13 dec. 2022
NL-Rotterdam-ERASMUSMC
2
22 nov. 2022
NL-Breda-AMPHIA
2
03 nov. 2022
BE-Antwerpen-ZNASTUIVENBERG
2
29 sep. 2022
BE-Gent-UZGENT
2
13 sep. 2022
NL-Den Haag-HAGA
1
05 dec. 2022
NL-Maastricht-MUMC
1
28 nov. 2022
NL-Amsterdam-VUMC
1
08 nov. 2022
NL-Nijmegen-CWZ
27 dec. 2022
BE-Bruxelles-STLUC
NL-Nieuwegein-ANTONIUS
15 dec. 2022
NL-Enschede-MST
BE-Antwerpen-ZNAMIDDELHEIM
29 sep. 2022
BE-Leuven-UZLEUVEN
CH-Zürich-USZ
= Active hospitals 
= Inactive hospitals